https://orcid.org/0000-0003-1235-8950
Key Points
APC cleavage and A2 dissociation both contribute to in vivo FVIIIa inactivation.
FIXa and FX modulate mechanisms of FVIIIa inactivation.
Subjects:
Thrombosis and Hemostasis
Abstract
Deficiency of factor VIII (FVIII) causes hemophilia A (HA), and excess FVIII function increases venous thromboembolic risk. The phenotypic consequences of aberrant FVIII function underscore the importance of understanding mechanisms that downregulate activated FVIII (FVIIIa) to inform disease pathology and therapeutic drug design. Spontaneous A2-domain dissociation and activated protein C (APC) proteolysis are established mechanisms of FVIIIa inactivation. However, we know very little about how FVIIIa binding interactions with FIXa and FX affect FVIIIa inactivation in vivo. Here, we investigate this using recombinant FVIIIa variants to probe A2-domain dissociation (FVIIIa-D519V,E665V) and APC cleavage (FVIIIa-R336Q,R562Q), or both (FVIIIa-R336Q,R562Q/D519V,E665V), in biochemical assays and in HA mouse injury models. We found that FIXa binding to FVIIIa stabilized the A2 domain and increased the contribution of APC to FVIIIa inactivation. Additional studies using individual APC cleavage site variants (FVIIIa-R336Q and FVIIIa-R562Q) demonstrated that FIXa and FX can protect FVIIIa from APC cleavage at Arg562 and Arg336, respectively, in a manner that is incomplete in vivo. Data also demonstrate that APC inactivation of FVIIIa exceeds FVIII, suggesting differential APC recognition of FVIIIa relative to FVIII. Hemostatic studies of FVIII variants with altered inactivation demonstrated that both A2-domain dissociation and APC cleavage contribute to in vivo FVIIIa regulation. Specifically, stabilizing the A2 domain, inhibiting APC cleavage, or both, improved potency 2.4-, 4.8-, and >10-fold, respectively, over wild-type FVIII in a mouse hemostatic assay. Data support that both mechanisms of FVIIIa inactivation and FIXa interactions could be leveraged to enhance FVIII function for therapeutic benefit.
Subjects:
Thrombosis and Hemostasis
References
1.
Mannucci
PM
, Tuddenham
EGD
. The hemophilias — from royal genes to gene therapy
. N Engl J Med
. 2001
;344
(23
):1773
-1779
.2.
Rietveld
IM
, Lijfering
WM
, le Cessie
S
, et al. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor
. J Thromb Haemost
. 2019
;17
(1
):99
-109
.3.
Jenkins
PV
, Rawley
O
, Smith
OP
, O'Donnell
JS
. Elevated factor VIII levels and risk of venous thrombosis
. Br J Haematol
. 2012
;157
(6
):653
-663
.4.
Kraaijenhagen
RA
, in't Anker
PS
, Koopman
MM
, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism
. Thromb Haemost
. 2000
;83
(1
):5
-9
.5.
Leavitt
AD
, Kavakli
K
, Frenzel
L
, et al. Efficacy and safety of giroctocogene fitelparvovec in adults with moderately severe to severe hemophilia Α: primary analysis results from the phase 3 ΑFFINE gene therapy trial
. Blood
. 2024
;144
(suppl 1
):1053
.6.
Samelson-Jones
BJ
, Doshi
BS
, George
LA
. Coagulation factor VIII: biological basis of emerging hemophilia A therapies
. Blood
. 2024
;144
(21
):2185
-2197
.7.
Mertens
K
, Cupers
R
, Van Wijngaarden
A
, Bertina
RM
. Binding of human blood-coagulation Factors IXa and X to phospholipid membranes
. Biochem J
. 1984
;223
(3
):599
-605
.8.
van Dieijen
G
, Tans
G
, Rosing
J
, Hemker
HC
. The role of phospholipid and factor VIIIa in the activation of bovine factor X
. J Biol Chem
. 1981
;256
(7
):3433
-3442
.9.
Fay
PJ
, Beattie
TL
, Regan
LM
, O'Brien
LM
, Kaufman
RJ
. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase: role of subunit dissociation and factor IXa-catalyzed proteolysis (∗)
. J Biol Chem
. 1996
;271
(11
):6027
-6032
.10.
Rosenberg
JS
, McKenna
PW
, Rosenberg
RD
. Inhibition of human factor IXa by human antithrombin
. J Biol Chem
. 1975
;250
(23
):8883
-8888
.11.
Johnson
DJD
, Langdown
J
, Huntington
JA
. Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-Å structure of the ternary complex
. Proc Natl Acad Sci U S A
. 2010
;107
(2
):645
-650
.12.
Chattopadhyay
R
, Sengupta
T
, Majumder
R
. Inhibition of intrinsic Xase by protein S
. Arterioscler Thromb Vasc Biol
. 2012
;32
(10
):2387
-2393
.13.
Heeb
MJ
, Cabral
KM
, Ruan
L
. Down-regulation of factor IXa in the factor Xase complex by protein Z-dependent protease inhibitor
. J Biol Chem
. 2005
;280
(40
):33819
-33825
.14.
Schmaier
AH
, Dahl
LD
, Rozemuller
AJ
, et al. Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa
. J Clin Invest
. 1993
;92
(5
):2540
-2545
.15.
Lu
G
, Broze
GJ
, Krishnaswamy
S
. Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III
. J Biol Chem
. 2004
;279
(17
):17241
-17249
.16.
Yang
L
, Manithody
C
, Qureshi
SH
, Rezaie
AR
. Contribution of exosite occupancy by heparin to the regulation of coagulation proteases by antithrombin
. Thromb Haemost
. 2010
;103
(2
):277
-283
.17.
Lollar
P
, Parker
ET
. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog
. J Biol Chem
. 1991
;266
(19
):12481
-12486
.18.
Fay
PJ
, Smudzin
TM
, Walker
FJ
. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity
. J Biol Chem
. 1991
;266
(30
):20139
-20145
.19.
Walker
FJ
, Chavin
SI
, Fay
PJ
. Inactivation of factor VIII by activated protein C and protein S
. Arch Biochem Biophys
. 1987
;252
(1
):322
-328
.20.
Pipe
SW
, Montgomery
RR
, Pratt
KP
, Lenting
PJ
, Lillicrap
D
. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A
. Blood
. 2016
;128
(16
):2007
-2016
.21.
Hultin
MB
, Jesty
J
. The activation and inactivation of human factor VIII by thrombin: effect of inhibitors of thrombin
. Blood
. 1981
;57
(3
):476
-482
.22.
Duncan
EM
, Duncan
BM
, Tunbridge
LJ
, Lloyd
JV
. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A
. Br J Haematol
. 1994
;87
(4
):846
-848
.23.
Hakeos
WH
, Miao
H
, Sirachainan
N
, et al. Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy
. Thromb Haemost
. 2002
;88
(5
):781
-787
.24.
McGinniss
MJ
, Kazazian
HH
, Hoyer
LW
, Bi
L
, Inaba
H
, Antonarakis
SE
. Spectrum of mutations in CRM-positive and CRM-reduced hemophilia A
. Genomics
. 1993
;15
(2
):392
-398
.25.
Pipe
SW
, Eickhorst
AN
, McKinley
SH
, Saenko
EL
, Kaufman
RJ
. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo
. Blood
. 1999
;93
(1
):176
-183
.26.
Pipe
SW
, Saenko
EL
, Eickhorst
AN
, Kemball-Cook
G
, Kaufman
RJ
. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa
. Blood
. 2001
;97
(3
):685
-691
.27.
Rudzki
Z
, Duncan
EM
, Casey
GJ
, Neumann
M
, Favaloro
EJ
, Lloyd
JV
. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII: C methods
. Br J Haematol
. 1996
;94
(2
):400
-406
.28.
Leong
L
, Sim
D
, Patel
C
, et al. Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models
. Blood
. 2015
;125
(2
):392
-398
.29.
Lu
D
, Kalafatis
M
, Mann
KG
, Long
GL
. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V
. Blood
. 1996
;87
(11
):4708
-4717
.30.
Wilhelm
AR
, Parsons
NA
, Samelson-Jones
BJ
, et al. Activated protein C has a regulatory role in factor VIII function
. Blood
. 2021
;137
(18
):2532
-2543
.31.
Sternberg
AR
, Martos-Rus
C
, Davidson
RJ
, Liu
X
, George
LA
. Pre-clinical evaluation of an enhanced-function factor VIII variant for durable hemophilia A gene therapy in male mice
. Nat Commun
. 2024
;15
(1
):7193
.32.
Lollar
P
, Knutson
GJ
, Fass
DN
. Stabilization of thrombin-activated porcine factor VIII:C by factor IXa phospholipid
. Blood
. 1984
;63
(6
):1303
-1308
.33.
Lamphear
BJ
, Fay
PJ
. Factor IXa enhances reconstitution of factor VIIIa from isolated A2 subunit and A1/A3-C1-C2 dimer
. J Biol Chem
. 1992
;267
(6
):3725
-3730
.34.
Regan
LM
, Lamphear
BJ
, Huggins
CF
, Walker
FJ
, Fay
PJ
. Factor IXa protects factor VIIIa from activated protein C. Factor IXa inhibits activated protein C-catalyzed cleavage of factor VIIIa at Arg562
. J Biol Chem
. 1994
;269
(13
):9445
-9452
.35.
Lapan
KA
, Fay
PJ
. Localization of a factor X interactive site in the A1 subunit of factor VIIIa
. J Biol Chem
. 1997
;272
(4
):2082
-2088
.36.
Regan
LM
, O'Brien
LM
, Beattie
TL
, Sudhakar
K
, Walker
FJ
, Fay
PJ
. Activated protein C-catalyzed proteolysis of factor VIIIa alters its interactions within factor Xase
. J Biol Chem
. 1996
;271
(8
):3982
-3987
.37.
O'Brien
LM
, Mastri
M
, Fay
PJ
. Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase
. Blood
. 2000
;95
(5
):1714
-1720
.38.
Lottenberg
R
, Jackson
CM
. Solution composition dependent variation in extinction coefficients for p-nitroaniline
. Biochim Biophys Acta
. 1983
;742
(3
):558
-564
.39.
Bunce
MW
, Toso
R
, Camire
RM
. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro
. Blood
. 2011
;117
(1
):290
-298
.40.
Basavaraj
MG
, Krishnaswamy
S
. Exosite binding drives substrate affinity for the activation of coagulation factor X by the intrinsic Xase complex
. J Biol Chem
. 2020
;295
(45
):15198
-15207
.41.
Baugh
RJ
, Krishnaswamy
S
. Role of the activation peptide domain in human factor X activation by the extrinsic Xase complex
. J Biol Chem
. 1996
;271
(27
):16126
-16134
.42.
Buddai
SK
, Toulokhonova
L
, Bergum
PW
, Vlasuk
GP
, Krishnaswamy
S
. Nematode anticoagulant protein c2 reveals a site on factor Xa that is important for macromolecular substrate binding to human prothrombinase
. J Biol Chem
. 2002
;277
(29
):26689
-26698
.43.
Di Scipio
RG
, Hermodson
MA
, Yates
SG
, Davie
EW
. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S
. Biochemistry
. 1977
;16
(4
):698
-706
.44.
Fujikawa
K
, Legaz
ME
, Kato
H
, Davie
EW
. The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XIa (activated plasma thromboplastin antecedent)
. Biochemistry
. 1974
;13
(22
):4508
-4516
.45.
Lundblad
RL
, Kingdon
HS
, Mann
KG
. Thrombin
. Methods Enzymol
. 1976
;45
:156
-176
.46.
Lollar
P
, Fass
DN
. Inhibition of activated porcine Factor IX by dansyl-glutamyl-glycyl-arginyl-chloromethylketone
. Arch Biochem Biophys
. 1984
;233
(2
):438
-446
.47.
Pittman
DD
, Alderman
EM
, Tomkinson
KN
, Wang
JH
, Giles
AR
, Kaufman
RJ
. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted FVIII
. Blood
. 1993
;81
(11
):2925
-2935
.48.
Wakabayashi
H
, Griffiths
AE
, Fay
PJ
. Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutations
. J Thromb Haemost
. 2009
;7
(3
):438
-444
.49.
Sabatino
DE
, Freguia
CF
, Toso
R
, et al. Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model
. Blood
. 2009
;114
(20
):4562
-4565
.50.
Curtis
JE
, Helgerson
SL
, Parker
ET
, Lollar
P
. Isolation and characterization of thrombin-activated human factor VIII
. J Biol Chem
. 1994
;269
(8
):6246
-6251
.51.
Lollar
P
, Parker
CG
. Subunit structure of thrombin-activated porcine factor VIII
. Biochemistry
. 1989
;28
(2
):666
-674
.52.
Waters
EK
, Hilden
I
, Sørensen
BB
, Ezban
M
, Holm
PK
. Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive
. J Thromb Haemost
. 2015
;13
(11
):2041
-2052
.53.
Seth Chhabra
E
, Liu
T
, Kulman
J
, et al. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice
. Blood
. 2020
;135
(17
):1484
-1496
.54.
Bi
L
, Lawler
AM
, Antonarakis
SE
, High
KA
, Gearhart
JD
, Kazazian
HH
. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
. Nat Genet
. 1995
;10
(1
):119
-121
.55.
Ivanciu
L
, Toso
R
, Margaritis
P
, et al. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia
. Nat Biotechnol
. 2011
;29
(11
):1028
-1033
.56.
Gale
AJ
, Cramer
TJ
, Rozenshteyn
D
, Cruz
JR
. Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V
. J Biol Chem
. 2008
;283
(24
):16355
-16362
.57.
Duffy
EJ
, Parker
ET
, Mutucumarana
VP
, Johnson
AE
, Lollar
P
. Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles
. J Biol Chem
. 1992
;267
(24
):17006
-17011
.58.
Lollar
P
, Parker
ET
, Curtis
JE
, et al. Inhibition of human factor VIIIa by anti-A2 subunit antibodies
. J Clin Invest
. 1994
;93
(6
):2497
-2504
.59.
Wakabayashi
H
, Varfaj
F
, Deangelis
J
, Fay
PJ
. Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface
. Blood
. 2008
;112
(7
):2761
-2769
.60.
Koppelman
SJ
, van Hoeij
M
, Vink
T
, et al. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C
. Blood
. 1996
;87
(6
):2292
-2300
.61.
Fay
PJ
, Beattie
T
, Huggins
CF
, Regan
LM
. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site
. J Biol Chem
. 1994
;269
(32
):20522
-20527
.62.
Lamphear
BJ
, Fay
PJ
. Proteolytic interactions of factor IXa with human factor VIII and factor VIIIa
. Blood
. 1992
;80
(12
):3120
-3126
.63.
Samelson-Jones
BJ
, Arruda
VR
. Protein-engineered coagulation factors for hemophilia gene therapy
. Mol Ther Methods Clin Dev
. 2019
;12
:184
-201
.64.
Lenting
PJ
, Donath
MJ
, van Mourik
JA
, Mertens
K
. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII
. J Biol Chem
. 1994
;269
(10
):7150
-7155
.65.
Lenting
PJ
, van de Loo
JW
, Donath
MJ
, van Mourik
JA
, Mertens
K
. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX
. J Biol Chem
. 1996
;271
(4
):1935
-1940
.66.
Walker
FJ
, Sexton
PW
, Esmon
CT
. The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V
. Biochim Biophys Acta
. 1979
;571
(2
):333
-342
.67.
Nesheim
ME
, Canfield
WM
, Kisiel
W
, Mann
KG
. Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C
. J Biol Chem
. 1982
;257
(3
):1443
-1447
.68.
Suzuki
K
, Stenflo
J
, Dahlbäck
B
, Teodorsson
B
. Inactivation of human coagulation factor V by activated protein C
. J Biol Chem
. 1983
;258
(3
):1914
-1920
.69.
Norstrøm
EA
, Tran
S
, Steen
M
, Dahlbäck
B
. Effects of factor Xa and protein S on the individual activated protein C-mediated cleavages of coagulation factor Va
. J Biol Chem
. 2006
;281
(42
):31486
-31494
.70.
Yegneswaran
S
, Kojima
Y
, Nguyen
PM
, Gale
AJ
, Heeb
MJ
, Griffin
JH
. Factor Va Residues 311–325 represent an activated protein C binding region
. J Biol Chem
. 2007
;282
(39
):28353
-28361
.71.
Yegneswaran
S
, Nguyen
PM
, Gale
AJ
, Griffin
JH
. Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C
. Thromb Haemost
. 2009
;101
(1
):55
-61
.72.
Rosing
J
, Hoekema
L
, Nicolaes
GA
, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C
. J Biol Chem
. 1995
;270
(46
):27852
-27858
.73.
Tran
S
, Norstrøm
E
, Dahlbäck
B
. Effects of prothrombin on the individual activated protein C-mediated cleavages of coagulation factor Va
. J Biol Chem
. 2008
;283
(11
):6648
-6655
.74.
Panteleev
MA
, Ananyeva
NM
, Greco
NJ
, Ataullakhanov
FI
, Saenko
EL
. Factor VIIIa regulates substrate delivery to the intrinsic factor X-activating complex
. The FEBS J
. 2006
;273
(2
):374
-387
.75.
Siner
JI
, Iacobelli
NP
, Sabatino
DE
, et al. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype
. Blood
. 2013
;121
(21
):4396
-4403
.76.
Bertina
RM
, Koeleman
BP
, Koster
T
, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C
. Nature
. 1994
;369
(6475
):64
-67
.77.
Camire
RM
, Kalafatis
M
, Cushman
M
, Tracy
RP
, Mann
KG
, Tracy
PB
. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals (∗)
. J Biol Chem
. 1995
;270
(35
):20794
-20800
.78.
Kalafatis
M
, Bertina
RM
, Rand
MD
, Mann
KG
. Characterization of the molecular defect in factor VR506A(∗)
. J Biol Chem
. 1995
;270
(8
):4053
-4057
.79.
Dahlbäck
B
, Carlsson
M
, Svensson
PJ
. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C
. Proc Natl Acad Sci U S A
. 1993
;90
(3
):1004
-1008
.80.
Dahlbäck
B
. Resistance to activated protein C, the Arg506 to gin mutation in the factor V gene, and venous thrombosis
. Thromb Haemost
. 1995
;73
(05
):739
-742
.81.
Rosendaal
FR
, Koster
T
, Vandenbroucke
JP
, Reitsma
PH
. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
. Blood
. 1995
;85
(6
):1504
-1508
.82.
Dahlbäck
B
. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis
. Thromb Haemost
. 1997
;78
(1
):483
-488
.83.
Koster
T
, Blann
AD
, Briët
E
, Vandenbroucke
JP
, Rosendaal
FR
. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis
. Lancet
. 1995
;345
(8943
):152
-155
.84.
George
LA
, Sullivan
SK
, Giermasz
A
, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant
. N Engl J Med
. 2017
;377
(23
):2215
-2227
.85.
Pipe
SW
, Leebeek
FWG
, Recht
M
, et al. Gene therapy with etranacogene dezaparvovec for Hemophilia B
. N Engl J Med
. 2023
;388
(8
):706
-718
.86.
Mahlangu
J
, Kaczmarek
R
, von Drygalski
A
, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A
. N Engl J Med Overseas Ed
. 2023
;388
(8
):694
-705
.87.
George
LA
, Monahan
PE
, Eyster
ME
, et al. Multiyear factor VIII expression after AAV gene transfer for hemophilia A
. N Engl J Med
. 2021
;385
(21
):1961
-1973
.88.
Leavitt
AD
, Konkle
BA
, Stine
KC
, et al. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
. Blood
. 2024
;143
(9
):796
-806
.89.
Samelson-Jones
BJ
, George
LA
. Adeno-associated virus gene therapy for hemophilia
. Annu Rev Med
. 2023
;74
:231
-247
.90.
Moser
KA
, Adcock Funk
DM
. Chromogenic factor VIII activity assay
. Am J Hematol
. 2014
;89
(7
):781
-784
.© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2025
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal